Navigation Links
Tigris Pharmaceuticals Presents Results of Breast Cancer Research at AACR Annual Meeting
Date:4/30/2009

>

AFP464 is nearing completion of Phase I clinical testing at Jules Bordet Institute in Belgium, Institut Gustav Roussy in Paris, Mayo Clinic in Rochester, Minnesota, Karmanos Cancer Institute in Detroit and University of Maryland Marlene and Stewart Greenebaum Cancer Center in Baltimore. Tigris Pharmaceuticals expects to soon move to Phase II clinical studies, including studies in triple-negative breast cancer patients with the drug alone or in combination with vorinostat, depending on the molecular gene profile subtypes of the patients. Triple-negative breast cancer afflicts mostly young women under the age of 40 and is more prevalent in the African-American and Hispanic community. About 182,460 women in the United States were diagnosed with invasive breast cancer in 2008, approximately 15-18% of which are triple negative, and about 40,480 will die from the disease, according to the American Cancer Society.

"Patients with triple negative breast cancer do not benefit from endocrine therapy or molecularly targeted therapy such as trastuzumab because they lack the targets for these drugs," said Dr. Binh Nguyen, M.D., Ph.D., Chief Medical Officer of Tigris. "The potential of using molecular gene profile to target the appropriate patient population that most likely could benefit from the treatment with AFP-464 is the right direction in the clinical development of this difficult to treat disease."

About AFP-464

AFP-464, a Lysol prodrug of aminoflavone (AF), undergoes rapid conversion to AF by nonspecific plasma esterases. It has shown a unique pattern of growth inhibitory activity in the NCI's 60 tumor cell line screen, with breast, ovarian, lung and renal lines exhibiting particular sensitivity. The mechanism of action of AF is believed to be that treatment with AF results in translocation of the arylhydrocarbon receptor (AhR; a transcriptional regulator of CYP1A1) from the cytoplasm to the nucleus,
'/>"/>

SOURCE Tigris Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. FDA Accepts Investigational New Drug (IND) Application for Tigris Pharmaceuticals GGTI-2418
2. Tigris Pharmaceuticals Files IND Application for GGTI-2418
3. Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009
4. OncoGenex Pharmaceuticals to Release First Quarter Financial Results
5. Vanda Pharmaceuticals Reports First Quarter 2009 Results
6. Onyx Pharmaceuticals Announces First Quarter 2009 Financial Results Teleconference and Webcast
7. Transcept Pharmaceuticals to Present at the Bank of America and Merrill Lynch 2009 Health Care Conference
8. Inimex Pharmaceuticals begins First Clinical Study of an Innate Defense Regulator
9. Cadence Pharmaceuticals Announces Presentations at Upcoming Scientific Conferences
10. Santaris Pharma Delivers Six LNA-Based RNA Inhibitors to Enzon Pharmaceuticals Ahead of Schedule
11. Peregrine Pharmaceuticals Reports Positive Data in Second Phase II Bavituximab Breast Cancer Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 30, 2014 Nematicide is a type ... are microscopic parasitic roundworms, found in massive quantities ... plants and animals. Nematicides have tended to be ... promoting migration through the soil. A single gram ... nematodes. With more than 10,000 species classified, they ...
(Date:9/30/2014)... September 30, 2014 Follow us ... of each type of cholesterol carrier or lipoprotein in ... of excessive cholesterol levels in the body, especially along ... to heart attack and other cardiovascular disorders. Cardiovascular Diseases ... testing for cholesterol levels on a regular basis, to ...
(Date:9/30/2014)... BUDAPEST, Hungary , September 30, 2014 /PRNewswire/ ... libraries and intuitive browsing of chemistry in documents ... providing chemistry software solutions and consulting services for ... extract chemical information and generate Markush structures from ... securing an organizations intellectual property, however generating and ...
(Date:9/30/2014)...  KemPharm, Inc., a clinical-stage specialty pharmaceutical company ... new molecular entity (NME) prodrugs, announced today that ... issued U.S. Patent No. 8,816,083 to KemPharm for ... Derivatives and Heteroaryl Carboxylic Acid Conjugates of Hydromorphone, ... The patent, which extends through 2032, provides ...
Breaking Biology Technology:Nematicides Market by Types (Fumigants, Organophosphates, Carbamate and Bio-Nematicides), Applications (Agrochemicals, Industrial, and Others), and Geography (North America, Europe, Asia-Pacific & ROW) - Global Trends & Forecasts to 2019 2Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 2Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 3Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 4ChemAxon Introduces ChemCurator for Chemical Information Extraction and Markush Structure Creation 2KemPharm, Inc. Receives Patent from the USPTO for Novel Prodrug of Hydromorphone, KP511 2
... /PRNewswire-Asia-FirstCall/ -- American Oriental Bioengineering, Inc. (NYSE: ... pharmaceutical company dedicated to improving health through the ... of prescription and over–the-counter ("OTC") products, today announced ... 31, 2011. First Quarter 2011 ...
... May 9, 2011 Netsmart Technologies, Inc., ... and human services organizations, today announced that Michael Valentine ... Valentine will join Netsmart from Cerner Corporation, where he ... He will succeed James Conway, who is retiring after ...
... SUNNYVALE, Calif., May 9, 2011 Accuray ... in the field of radiosurgery, announced today that the ... company,s Form S-4 Registration Statement relating to the previously ... statement/prospectus contained in the registration statement will first be ...
Cached Biology Technology:American Oriental Bioengineering Reports First Quarter 2011 Financial Results 2American Oriental Bioengineering Reports First Quarter 2011 Financial Results 3American Oriental Bioengineering Reports First Quarter 2011 Financial Results 4American Oriental Bioengineering Reports First Quarter 2011 Financial Results 5Netsmart Technologies Names Michael Valentine as Chief Executive Officer 2Netsmart Technologies Names Michael Valentine as Chief Executive Officer 3SEC Declares Accuray Form S-4 Registration Statement Effective in Proposed Acquisition of TomoTherapy 2SEC Declares Accuray Form S-4 Registration Statement Effective in Proposed Acquisition of TomoTherapy 3SEC Declares Accuray Form S-4 Registration Statement Effective in Proposed Acquisition of TomoTherapy 4
(Date:9/30/2014)... September 30, 2014--Sea monkeys have captured the popular attention ... easily observable life cycle -- sold as dehydrated eggs, ... given little more than a tank of salt water. ... pattern: Like other zooplankton, brine shrimp vertically migrate in ... closer to the surface at night and retreating deeper ...
(Date:9/30/2014)... and engineers, led by Clemson University associate professor ... grant from the U.S. Department of Energy,s Experimental ... direct positive impact on South Carolina in the ... contaminants. , "Understanding the scientific and engineering needs ... of nuclear technologies is imperative if South Carolina ...
(Date:9/30/2014)... almost any aquatic environment on Earth, but when the ... pushed to the limit. The amount of time needed ... how different species cope in the future, reveals a ... published in the scientific journal Proceedings of the ... thanks to increasing levels of greenhouse gases in the ...
Breaking Biology News(10 mins):Laser-guided sea monkeys show how zooplankton migrations may affect global ocean currents 2Researchers get $5.25 million to advance nuclear technologies in South Carolina 2Shape up quickly -- applies to fish, too! 2
... thought to be only a structural support protein in the ... its cross-like shape. However, laminin is far more ... studies led by one of the world,s foremost breast cancer ... the development of breast cancer, ,the second most common cancer ...
... development, sensory and motor fibers interact to form nerves ... Andrea Huber Brsamle of the Institute of Developmental Genetics ... interaction functions at the molecular level: The cell surface ... nerve fibers and controls their interaction in order to ...
... All our daily activities, from driving to work to solving ... vast network of neurons. Propagation of these signals is, in ... receptors, ion channels, and transmitters -- turning on and off ... in real time has not been possible, but researchers at ...
Cached Biology News:Berkeley Lab researchers illuminate laminin's role in cancer formation 2Berkeley Lab researchers illuminate laminin's role in cancer formation 3Berkeley Lab researchers illuminate laminin's role in cancer formation 4Berkeley Lab researchers illuminate laminin's role in cancer formation 5
ANTI CORTIS BIN GLOB...
ANTI S. ENTERID LPS...
... Development kit contains the basic components required ... measure natural and recombinant rat L-Selectin in ... kit contains sufficient materials to run ELISAs ... the following conditions are met: ...
...
Biology Products: